Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 31, 2017. The document serves as a transaction notification regarding dealings by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them, rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly limited to disclosing specific share transactions and contains no consolidated financial statements or operational metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific internal share transfer event dated May 30, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of a share transfer.
Important Facts for Investors
- Transaction Type: Transfer of 7,875 Ordinary Shares (ISIN: GB0009252882) for nil consideration.
- Parties Involved: Mr. R G Connor (President, Global Manufacturing & Supply) transferred shares to his spouse, Mrs. D Connor.
- Transaction Date: May 30, 2017.
- Price: £0.00 per share.
- Signatory: Victoria Whyte, Authorised Signatory for GlaxoSmithKline plc.